Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Deferred Revenue (2016 - 2020)

Amicus Therapeutics (FOLD) has disclosed Current Deferred Revenue for 8 consecutive years, with $1.2 million as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Current Deferred Revenue fell 54.55% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Mar 2020, down 54.55%, and an annual FY2019 reading of $1.2 million, down 77.27% over the prior year.
  • Current Deferred Revenue was $1.2 million for Q1 2020 at Amicus Therapeutics, roughly flat from $1.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $18.8 million in Q2 2017 and bottomed at $1.2 million in Q4 2019.
  • Average Current Deferred Revenue over 5 years is $6.6 million, with a median of $5.4 million recorded in 2018.
  • The sharpest move saw Current Deferred Revenue tumbled 85.41% in 2018, then soared 90.91% in 2019.
  • Year by year, Current Deferred Revenue stood at $13.8 million in 2016, then tumbled by 44.04% to $7.8 million in 2017, then dropped by 29.03% to $5.5 million in 2018, then plummeted by 77.27% to $1.2 million in 2019, then changed by 0.0% to $1.2 million in 2020.
  • Business Quant data shows Current Deferred Revenue for FOLD at $1.2 million in Q1 2020, $1.2 million in Q4 2019, and $5.2 million in Q3 2019.